Appoints Kurt Knab as Vice President, Sales
Appoints Alejandro “Alex” Sabad as Vice President, Operations
Appoints Amy Marinne Fox as Vice President, Human Resources
IRVINE, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a company dedicated to aesthetic medicine, today announced the expansion of its leadership team with the appointments of three key executives reporting to David Moatazedi, President and Chief Executive Officer. Evolus has appointed Kurt Knab as Vice President of Sales, Alejandro “Alex” Sabad as Vice President of Operations and Amy Marinne Fox as Vice President of Human Resources. Each new executive has a proven track record of excellence in their respective fields of expertise and adds decades of experience to the Evolus leadership team.
David Moatazedi commented, “Evolus continues to attract accomplished talent in the industry, and we are pleased to announce the addition of these seasoned leaders to our team. Their exceptional backgrounds and industry knowledge complete our leadership team as we rapidly advance towards anticipated FDA approval in February 2019 and expected commercial launch in Spring 2019.”
Mr. Knab joins Evolus from Medline Industries where he served as Vice President of Business Development and Sales. Prior to that, Kurt spent sixteen years at LifeCell Corporation where he held various roles in sales leadership and ultimately served as Vice President, U.S. Sales for 4 years. At LifeCell he was responsible for leading the commercial efforts of the LifeCell’s entire portfolio including Alloderm®, Strattice®, and Revolve®. Mr. Knab has over 20 years of commercial and executive experience with top performing medical device companies. He spent the early part of his career with Pfizer and Mitek Products, an Ethicon Company, developing high growth markets. Kurt earned a BS in Marketing from Penn State University.
Mr. Sabad brings over 25 years of combined industry & consulting experience with a range of life science companies and is recognized for his expertise in global manufacturing and operations. Mr. Sabad formerly served as a Managing Director at Deloitte Consulting where he served as the Technical Operations Solution and Global Manufacturing Strategy & Operations Lead and led the Contract Development and Manufacturing Organizations (CDMO) segment for the practice. Prior to Deloitte, he served as Vice President of Operations Strategy and Network Performance Management at MedImmune, AstraZeneca’s global biologics division which contributed over $1.0 billion of annual revenue. Mr. Sabad received an MBA in Strategy & Finance from the Mendoza School of Business at the University of Notre Dame and a BA from the University of California, Los Angeles.
Ms. Fox has over 20 years of experience building high performing, agile organizations. Ms. Fox previously served as Vice President, Human Resources of Orexigen Therapeutics, where she led the design of employee retention programs and global HR capabilities to meet organizational demands with system implementations, metrics and process improvements. Prior to Orexigen, she served as Director of Human Resources at Synteract, a global Clincal Research Organization specializing in the delivery of clinical trial solutions across multiple therapeutic areas. Previously, she served as a Human Resources Manager at Robbins Arroyo, a boutique law firm specializing in securities litigation. Ms. Fox earned a BA in Literature-Writing at the University of California San Diego.
About Evolus, Inc.
Evolus is a company dedicated to aesthetic medicine focused on providing physicians and their patients with expanded choices in aesthetic treatments and procedures. Evolus’ lead candidate DWP-450, also known by the chemical name prabotulinumtoxinA, is a 900 kDa purified botulinum toxin type A complex that was approved by Health Canada for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients under 65 years of age and is being evaluated for marketing approval in the United States and other areas.
Statements made in this press release that relate to future plans, events, prospects or performance are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words “planned,” “expect,” “believes,” “strategy,” “opportunity,” “anticipates,” “outlook,” “designed,” and similar words. While these forward-looking statements are based on the current expectations and beliefs of management, such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from the expectations expressed in this press release, including the risks and uncertainties disclosed in Evolus’ periodic filings with the Securities and Exchange Commission, including factors described in the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2017 and its Quarterly Report on Form 10-Q for the Quarter ended June 30, 2018, as filed with the Securities and Exchange Commission on March 29, 2018 and August 2, 2018, respectively, all of which are available online at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, Evolus undertakes no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events.
Ashwin Agarwal, Evolus
Brian Johnston, The Ruth Group
Tel: +1 646-536-7028
Kirsten Thomas, The Ruth Group
Dani Shaffer, Alison Brod Marketing + Communications
Alloderm®, Strattice®, and Revolve® are registered trademarks of LifeCell Corporation.